rLj-RGD3
proteinrLj-RGD3 inhibits platelet adhesion and aggregation by blocking integrin-mediated interaction with the thrombogenic substrate.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencehigh
RationaleRGD-motif disintegrin antagonizing platelet GPIIb/IIIa and collagen adhesion.
Druggability
Not assessed (no mapped human gene target).
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- rLj-RGD3, a novel recombinant toxin protein from Lampetra japonica, prevents coronary thrombosis-induced acute myocardial infarction by inhibiting platelet functions in rats.Biochemical and biophysical research communications · 2018 · PMID 29407168 · doi